D3L 001
Alternative Names: D3L-001Latest Information Update: 24 Oct 2023
At a glance
- Originator D3 Bio
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Breast cancer; Gastric cancer; Solid tumours
Most Recent Events
- 19 Sep 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Monotherapy) in USA (IV) (NCT05957536)
- 24 Jul 2023 D3 Bio plans a phase I trial for Solid tumours (Late-stage disease) in August 2023 (IV) (NCT05957536)
- 06 Jun 2023 Phase-I clinical trials in Breast cancer in China (Parenteral) (D3 Bio pipeline, June 2023)